What could explain the discordant results between PARP/abiraterone combinations in MAGNITUDE and PROpel in non-HRRm prostate cancer?

This is an important question. I would summarize this below:

1. Differences in study design and patient populations

• MAGNITUDE allowed prior ARSI (5%), prior exposure to abiraterone for up to 4 mo which could have been selected for patients less sensitive to abiraterone where PARPi combination syner...